Format

Send to

Choose Destination
Early Hum Dev. 2017 Feb;105:41-47. doi: 10.1016/j.earlhumdev.2016.12.007. Epub 2016 Dec 18.

Cardiac biomarkers and haemodynamically significant patent ductus arteriosus in preterm infants.

Author information

1
Department of Newborn and Developmental Paediatrics, Sunnybrook Health Sciences Centre, Toronto, Canada; Department of Paediatrics, University of Toronto, Toronto, Canada.
2
Department of Paediatrics, University of Toronto, Toronto, Canada; Department of Physiology, University of Toronto, Toronto, Ontario, Canada; Physiology and Experimental Medicine Program, SickKids Research Institute, Toronto, Canada.
3
Department of Neonatology, The Rotunda Hospital, Dublin, Ireland; School of Medicine (Department of Paediatrics), Royal College of Surgeons in Ireland, Dublin, Ireland. Electronic address: afifelkhuffash@rcsi.ie.

Abstract

Accurately defining haemodynamically significant patent ductus arteriosus (PDA) in preterm infants who are at risk of PDA related morbidities are active areas of neonatal research. Natriuretic peptides are cardiac hormones that respond to volume and pressure loading, with elevated plasma levels found in infants with PDA. In the preterm neonatal setting, studies to date have predominantly investigated the ability of these biomarkers to discriminate between infants with and without a PDA at various postnatal ages. Their clinical utility has therefore been exclusively evaluated as a method of triaging cases of suspected hsPDA to decrease the need for echocardiograms, and to monitor treatment response. Biomarkers are yet to be robustly investigated for their ability to predict important PDA associated morbidities. In this review, we examine the most recent literature to date on the use of biomarkers in the management of PDA.

KEYWORDS:

BNP; Biomarkers; Natriuretic peptides; PDA; Preterm Infants

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center